The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relationship between checkpoint molecule B7-H3 and refractoriness to anti-PD-1 therapy in non-small cell lung cancer.
 
Kimio Yonesaka
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Patents pending joint application with Daiichi-Sankyo
 
Keita Kudo
No Relationships to Disclose
 
Shiki Takamura
No Relationships to Disclose
 
Hitomi Sakai
No Relationships to Disclose
 
Ryoji Kato
No Relationships to Disclose
 
Koji Haratani
No Relationships to Disclose
 
Takayuki Takahama
No Relationships to Disclose
 
Kaoru Tanaka
No Relationships to Disclose
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Research Funding - Boehringer Ingelheim; Ono Pharmaceutical
 
Hiroyuki Kaneda
No Relationships to Disclose
 
Masayuki Takeda
No Relationships to Disclose
 
Osamu Maenishi
No Relationships to Disclose
 
Michiko Yamato
Employment - Daiichi Sankyo
 
Masaaki Miyazawa
No Relationships to Disclose
 
Kazuto Nishio
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EPS Holdings; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Showa Yakuhin Kako; SymBio Pharmaceuticals
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)